This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Dana-Farber-Cancer Institute Inc.. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: The Innovative Contributions of Mingxing Teng
Introduction
Mingxing Teng is a notable inventor based in Boston, MA. He has made significant contributions to the field of cancer research through his innovative work on CDK2/5 degraders. His research focuses on developing treatments for diseases associated with dysfunctional cyclin-dependent kinase 2 (CDK2) and CDK5 activity.
Latest Patents
Mingxing Teng holds a patent for his invention titled "CDK2/5 degraders and uses thereof." This patent encompasses bifunctional compounds, compositions, and methods aimed at treating various diseases or conditions mediated by CDK2 and CDK5 dysfunction. He has 1 patent to his name, showcasing his commitment to advancing medical science.
Career Highlights
Mingxing Teng is affiliated with the Dana-Farber Cancer Institute Inc., where he continues to push the boundaries of cancer treatment research. His work is instrumental in developing new therapeutic strategies that could potentially improve patient outcomes.
Collaborations
Mingxing collaborates with talented colleagues, including Katherine Donovan and Tinghu Zhang. Their combined expertise enhances the research efforts at the Dana-Farber Cancer Institute.
Conclusion
Mingxing Teng's innovative work in the field of cancer research exemplifies the impact of dedicated inventors on medical advancements. His contributions are paving the way for new treatment options that could benefit many patients in the future.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile